Gan & Lee Pharmaceuticals.
603087
Classement en actions
#3014
Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused... Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused on the discovery, development, manufacturing, and marketing of insulin analogues within the Chinese market. Their diverse product portfolio encompasses injectable therapies such as Basalin (an insulin glargine), Prandilin (an insulin lispro), Prandilin 25 (another insulin lispro variant), Raplin (an insulin aspart), Raplin 30 (an insulin aspart 30 formulation), and Similin 30 (an insulin injection). Beyond diabetes treatments, the company also offers various medical devices. Established in 1998, Gan & Lee Pharmaceuticals maintains its corporate headquarters in Beijing, People's Republic of China. The organization underwent a name change in April 2005, transitioning from its former identity as Beijing Gan & Lee Biotechnology Co., Ltd.
Prix de l'action
$10.03
Capitalisation boursière
$5.99B
Changement (1 jour)
-3.71%
Changement (1 an)
2.30%
Pays
CN
Échange Gan & Lee Pharmaceuticals. (603087)
Catégorie
Healthcare
Revenus pour Gan & Lee Pharmaceuticals. (603087)
Revenus en Oct 2026 TTM : 0
Selon les derniers rapports financiers de Gan & Lee Pharmaceuticals., le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Gan & Lee Pharmaceuticals. de 2013 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2025 | $577.49M | 38.41% |
| 2024 | $417.22M | 13.24% |
| 2023 | $368.44M | 48.43% |
| 2022 | $248.23M | -56.32% |
| 2021 | $568.30M | 10.43% |
| 2020 | $514.62M | 23.78% |
| 2019 | $415.76M | 19.79% |
| 2018 | $347.07M | -4.74% |
| 2017 | $364.35M | 42.80% |
| 2016 | $255.15M | 35.83% |
| 2015 | $187.84M | 25.57% |
| 2014 | $149.60M | 31.01% |
| 2013 | $114.19M | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| $11.58B | - |
US
|
|
| $34.74B | - |
FR
|
|
| - | - |
JP
|
|
| $20.84B | - |
US
|
|
| - | - |
CH
|
